IRON Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

IRON Financial’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$46K	–	108
2020 Q4	$46K	Buy	+10,000	New	+$44.3K	0.02%	121

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IRON Financial's AMRX Position: Q1 2021 in Review

IRON Financial sold out of Amneal Pharmaceuticals (AMRX) in Q1 2021, closing a stake of 10,000 shares — an estimated $46K sold.

IRON Financial first reported a position in AMRX in Q4 2020 and held it in 1 quarter. The position peaked at $46K in Q4 2020. 161 funds tracked by Wall St. Rank hold AMRX as of Q1 2021.

IRON Financial reported no remaining Amneal Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
IRON Financial sold 10,000 Amneal Pharmaceuticals shares in Q1 2021, an estimated $46K.
IRON Financial first reported a position in Amneal Pharmaceuticals in Q4 2020 and held it in 1 quarter.
IRON Financial's Amneal Pharmaceuticals position peaked at $46K in Q4 2020.
161 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2021.

Based on IRON Financial's 13F filing for Q1 2021, filed 7 May 2021.